


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:21Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405111" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405111</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405111</article-id><article-id pub-id-type="pmcid-ver">PMC12405111.1</article-id><article-id pub-id-type="pmcaid">12405111</article-id><article-id pub-id-type="pmcaiid">12405111</article-id><article-id pub-id-type="pmid">40892139</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03521-z</article-id><article-id pub-id-type="publisher-id">3521</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Preliminary study on SIRI dynamic changes for the efficacy prediction and prognosis evaluation of advanced cancer patients treated with immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wei</surname><given-names initials="X">Xiuzhen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yinghai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="H">Huijuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yang</surname><given-names initials="Q">Qingqing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="B">Baihong</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Q">Qianyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="L">Lingling</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="Z">Zhengjie</given-names></name><address><email>34628588@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Oncology, Wu Wei Liang Zhou Hospital, Wuwei, Gansu China </aff><aff id="Aff2"><label>2</label>Department of Gastroenterology, Wu Wei Liang Zhou Hospital, Wuwei, Gansu China </aff><aff id="Aff3"><label>3</label>Department of Oncology, 940th Hospital of Joint Logistics Support Force of People&#8217;s Liberation Army, Lanzhou, Gansu China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1673</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3521.pdf"/><abstract id="Abs1" abstract-type="structured"><sec><title>Objective</title><p id="Par1">To investigate the values of systemic inflammatory response index (SIRI) and its dynamic changes in predicting the efficacy and evaluating the prognosis of immunotherapy for advanced cancers.</p></sec><sec><title>Methods</title><p id="Par2">A retrospective analysis was conducted on the clinical data of 245 patients with locally advanced and advanced cancers who received immune checkpoint inhibitors (ICI) treatment at the 940 Hospital of the Joint Logistics Support Force from June 2020 to June 2023.The &#967;2-test was used to compare the clinical pathological characteristics of patients in the disease control group and the no-control group, and Kruskal-Wallis test was used to compare the differences in SIRI pre-treatment, disease remission, and disease progression. The correlation between SIRI and progression free survival (PFS) of patients was analyzed using Kaplan-Meier survival curve and Log-rank test; and factors affecting PFS in cancer patients receiving ICIs treatment were analyzed through univariate and multivariate COX regression analysis.</p></sec><sec><title>Results</title><p id="Par3">There was a significant difference in the number of treatment lines between the disease control group and no-control group (<italic toggle="yes">P</italic>&#8201;=&#8201;0.042), but no significant differences were observed in gender, age, tumor differentiation, number of metastatic organs and treatment plan between the two groups (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Compared with pre-treatment, the SIRI decreased during disease remission and increased again during disease progressed. Kaplan- Meier survival curves indicated that patients with high SIRI had shorter PFS than those with low SIRI (<italic toggle="yes">P&#8201;=</italic>&#8201;0.019, &lt;&#8201;0.001, 0.012). Univariate and multivariate COX regression analysis revealed that pre-treatment high SIRI (HR&#8201;=&#8201;2.804,95%CI 1.150&#8201;~&#8201;6.838, <italic toggle="yes">P</italic>&#8201;=&#8201;0.023) and disease remission high SIRI (HR&#8201;=&#8201;2.469,95%CI 1.513&#8201;~&#8201;4.029, <italic toggle="yes">P</italic>&lt;0.001) were independent risk factors for PFS in cancer patients undergoing immunotherapy.</p></sec><sec><title>Conclusion</title><p id="Par4">The inflammatory index SIRI can be a dynamic biomarker for evaluating the efficacy and prognosis of advanced cancer patients receiving ICI treatment.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Advanced cancer</kwd><kwd>Systemic inflammatory response index</kwd><kwd>Immunotherapy</kwd><kwd>Efficacy prediction</kwd><kwd>Prognosis prediction</kwd></kwd-group><funding-group><award-group><funding-source><institution>Wuwei Science and Technology Bureau</institution></funding-source><award-id>WW24B01SF087</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">According to the latest statistics from the International Agency for Research on Cancer, lung cancer is the most commonly occurring cancer globally, followed by breast cancer and colorectal cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. Traditional chemotherapy has proven to be less effective in treating advanced tumors. In recent years, immune checkpoint inhibitors (ICI), particularly those targeting programmed death protein ligand-1 (PD-L1) and programmed death receptor 1 (PD-1), have demonstrated significant efficacy against a range of tumors. Results from large-scale studies such as CheckMate 649 [<xref ref-type="bibr" rid="CR2">2</xref>], KEYNOTE-859 [<xref ref-type="bibr" rid="CR3">3</xref>], and KEYNOTE-189 [<xref ref-type="bibr" rid="CR4">4</xref>] indicate that patients with advanced gastric cancer and lung cancer who received ICI therapy experienced substantial benefits over those treated with chemotherapy in terms of progression-free survival (PFS) and overall survival. Although ICI has been shown to enhance the survival rates of patients with advanced tumors in both clinical trials and practice, some patients do not respond to immunotherapy. Consequently, identifying biomarkers to identify those who are most likely to benefit from immunotherapy is particularly critical.</p><p id="Par6">PD-L1, tumor mutational load, and microsatellite status are potential biomarkers currently used to identify the population most likely to benefit from immunotherapy [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. However, the detection methods for these factors are complex and costly, the accessibility of repeated measurements is limited, making it impossible to guide treatment dynamically. Furthermore, tumor mutation burden and microsatellite status cannot serve as biomarkers for all solid cancers, necessitating further tumor-type-specific research [<xref ref-type="bibr" rid="CR8">8</xref>]. Consequently, it is crucial to identify simple and affordable clinical markers that can predict the efficacy and prognosis of immunotherapy. Inflammation is closely associated with both tumors and immunity and plays a pivotal role in the initiation, progression, treatment, and prognosis of cancer [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. The systemic inflammatory response index (SIRI) is a novel serum marker that more comprehensively reflects the systemic immune and inflammatory status and has been found to correlate with the prognosis of advanced tumors, such as breast, lung, and liver cancers, treated with ICI [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Currently, research on inflammatory indicators and cancer primarily focuses on the relationship between baseline inflammatory indicators and the prognosis of cancer patients, while studies on the correlation between dynamic changes in inflammatory indicators and cancer are relatively scarce. The aim of this study is to investigate the changes in SIRI, an inflammatory index, in advanced cancer patients treated with ICI, before treatment, during disease remission, and at disease progression. Additionally, the study seeks to analyze the association between SIRI and patient prognosis to screen for the immune benefit population using simple peripheral blood indicators and to assess patient disease status promptly.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p id="Par7">
Strictly adhering to the inclusion and exclusion criteria, the clinicopathological and peripheral blood results of 245 patients with locally advanced or advanced tumors who received ICI treatment at the 940 Hospital of the Joint Service Support Force of the Chinese People&#8217;s Liberation Army between June 2020 and June 2023 were collected. The cancer patients included in this study comprised 85 cases of lung cancer (34.7%), 57 cases of gastric cancer (22.9%), 35 cases of liver cancer (14.3%), 10 cases of malignant melanoma (4.1%), 8 cases of esophageal cancer (3.3%), 8 cases of colorectal cancer (3.3%), 8 cases of cholangiocarcinoma (3.3%), 7 cases of gynecological tumors (2.9%), 6 cases of renal cancer (2.4%), 5 cases of pancreatic cancer (2.0%), 4 cases of nasopharyngeal carcinoma (1.6%), and 13 cases of other tumors (5.2%), as illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par8">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Tumor types</p></caption><graphic id="d33e289" position="float" orientation="portrait" xlink:href="12672_2025_3521_Fig1_HTML.jpg"/></fig>
</p><p id="Par9">
<italic toggle="yes">Inclusion criteria</italic>
</p><p id="Par10">
<list list-type="bullet"><list-item><p id="Par11">Patients with a clear pathological diagnosis of a malignant tumor in stage III or IV, as defined by the 8th edition of the American Joint Committee on Cancer TNM staging, who are inoperable;</p></list-item><list-item><p id="Par12">Those who have received at least two cycles of ICI treatment;</p></list-item><list-item><p id="Par13">At least one efficacy evaluation based on immune response evaluation criteria in solid tumor(iRECIST) criteria has been completed during treatment;</p></list-item><list-item><p id="Par14">Complete peripheral blood routine examination results are available before and after ICI treatment.</p></list-item></list>
</p><p id="Par15">
<italic toggle="yes">Exclusion criteria</italic>
</p><p id="Par16">
<list list-type="bullet"><list-item><p id="Par17">Patients with no evaluable lesions.</p></list-item><list-item><p id="Par18">Co-infection, liver disease, autoimmune disease, and other conditions that could affect the results of blood routine examinations;</p></list-item><list-item><p id="Par19">Patients with an Eastern Cooperative Oncology Group (ECOG) performance status score greater than 3;</p></list-item><list-item><p id="Par20">Patients with complications from other tumors, heart failure, liver and kidney dysfunction, and other serious medical conditions.</p></list-item><list-item><p id="Par21">Previously treated with immune checkpoint inhibitors;</p></list-item><list-item><p id="Par22">Those who received anti-tumor treatment in recent 2 weeks.</p></list-item></list>
</p><p id="Par23">All patients provided informed consent for immunotherapy prior to treatment.</p></sec><sec id="Sec4"><title>Collecting and defining clinical data</title><p id="Par24">Clinical data, including age, gender, ECOG score, tumor differentiation, metastatic organs, number of immunotherapy lines, and treatment plan were collected for patients. The efficacy was evaluated according to iRECIST [<xref ref-type="bibr" rid="CR8">8</xref>] (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), iCR, iPR and iSD were defined as disease control, while iCPD was considered no-controlled disease. If a patient&#8217;s initial efficacy evaluation indicated progression, the efficacy remission index data was missing. PFS was calculated from the initiation of ICI treatment until disease progression or death. Blood routine results were collected one week before ICI treatment, one month before the efficacy remission, and one month before disease progression.</p><p id="Par25">SIRI&#8201;=&#8201;neutrophil count * monocyte count / lymphocyte count.</p><p id="Par26">Patients&#8217; prognoses were followed up using inpatient and outpatient electronic medical records and telephone follow-ups until December 1, 2024.</p><p id="Par27">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>iRECIST criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Efficacy evaluation</th><th align="left" colspan="1" rowspan="1">iRECIST</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">iCR</td><td align="left" colspan="1" rowspan="1">Disappearance of all lesions</td></tr><tr><td align="left" colspan="1" rowspan="1">iPR</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;50% decrease from baseline</td></tr><tr><td align="left" colspan="1" rowspan="1">iSD</td><td align="left" colspan="1" rowspan="1">Neither iCR or iPD is met</td></tr><tr><td align="left" colspan="1" rowspan="1">iUPD</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;20% increase in the nadir of the sum of target lesions with a minimum of 5&#160;mm</td></tr><tr><td align="left" colspan="1" rowspan="1">iCPD</td><td align="left" colspan="1" rowspan="1">Yes, at least 4 weeks after, and up to 12 weeks</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par28">
SPSS 25.0 software and GraphPad Prism 8.0.2 were utilized for statistical analysis and data plotting. Non-normally distributed measurement data, such as SIRI, were described using the median (<italic toggle="yes">P</italic><sub>25</sub>, <italic toggle="yes">P</italic><sub>75</sub>), and the rank-sum test was employed for inter-group comparisons. Patients were categorized into a disease control group and a disease uncontrolled group based on disease progression. The number of use cases, expressed as percentages [n (%)], was statistically described for categorical data. Group differences were compared using the &#967;2 test or Fisher&#8217;s exact test. Depending on disease progression, receiver operating characteristic (ROC) curves were constructed. Patients were then divided into high Siri and low Siri groups according to the optimal threshold. Kaplan-Meier survival curves were employed for survival analysis, and the log-rank test was used to compare differences between groups. Univariate and multivariate COX regression analyses were conducted to screen for risk factors affecting PFS in patients with malignant tumors treated with ICI. A <italic toggle="yes">P</italic> value of less than 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p id="Par29">A total of 245 patients were included in this study, comprising 165 male patients (67.3%) and 80 female patients (32.7%). Of these, 164 patients (66.9%) received first-line ICI treatment, 48 patients (19.6%) received second-line ICI treatment, and 33 patients (13.5%) received third-line or higher ICI treatment. Regarding treatment modalities, 19 patients (7.8%) were treated with ICI monotherapy, 152 patients (62.0%) received ICI in combination with chemotherapy, and 74 patients (30.2%) were treated with ICI combined with chemotherapy and targeted therapy. Only the number of treatment lines exhibited a statistically significant difference between the disease control group and the disease uncontrolled group (<italic toggle="yes">P</italic>&#8201;=&#8201;0.042). In contrast, there were no statistically significant differences in the clinical characteristics of the two groups, such as gender, age, ECOG score, tumor location, tumor differentiation, number of metastatic organs and treatment plan and treatment plan (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05), as illustrated in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par30">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Clinicopathological features of control group and no-control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinicopathological features</th><th align="left" colspan="1" rowspan="1">Total patients<break/><italic toggle="yes">n</italic>&#8201;=&#8201;245</th><th align="left" colspan="1" rowspan="1">Control group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;77</th><th align="left" colspan="1" rowspan="1">No-control group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;168</th><th align="left" colspan="1" rowspan="1">&#967;2 value</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.112</td><td char="." align="char" colspan="1" rowspan="1">0.737</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td char="." align="char" colspan="1" rowspan="1">80 (32.7)</td><td char="." align="char" colspan="1" rowspan="1">24 (31.2)</td><td char="." align="char" colspan="1" rowspan="1">56 (33.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td char="." align="char" colspan="1" rowspan="1">165 (67.3)</td><td char="." align="char" colspan="1" rowspan="1">53 (68.8)</td><td char="." align="char" colspan="1" rowspan="1">112 (66.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.052</td><td char="." align="char" colspan="1" rowspan="1">0.819</td></tr><tr><td align="left" colspan="1" rowspan="1">&lt;60</td><td char="." align="char" colspan="1" rowspan="1">114 (46.5)</td><td char="." align="char" colspan="1" rowspan="1">35 (45.5)</td><td char="." align="char" colspan="1" rowspan="1">79 (47.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;60</td><td char="." align="char" colspan="1" rowspan="1">131 (53.5)</td><td char="." align="char" colspan="1" rowspan="1">42 (54.5)</td><td char="." align="char" colspan="1" rowspan="1">89 (53.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of metastatic organs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">1.102</td><td char="." align="char" colspan="1" rowspan="1">0.294</td></tr><tr><td align="left" colspan="1" rowspan="1">&lt;2</td><td char="." align="char" colspan="1" rowspan="1">112 (45.7)</td><td char="." align="char" colspan="1" rowspan="1">39 (50.6)</td><td char="." align="char" colspan="1" rowspan="1">73 (43.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;2</td><td char="." align="char" colspan="1" rowspan="1">133 (54.3)</td><td char="." align="char" colspan="1" rowspan="1">38 (49.4)</td><td char="." align="char" colspan="1" rowspan="1">95 (56.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor differentiation</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.109</td><td char="." align="char" colspan="1" rowspan="1">0.947</td></tr><tr><td align="left" colspan="1" rowspan="1">High/middle</td><td char="." align="char" colspan="1" rowspan="1">77 (31.6)</td><td char="." align="char" colspan="1" rowspan="1">24 (31.6)</td><td char="." align="char" colspan="1" rowspan="1">53 (31.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Low</td><td char="." align="char" colspan="1" rowspan="1">58 (23.8)</td><td char="." align="char" colspan="1" rowspan="1">19 (25.0)</td><td char="." align="char" colspan="1" rowspan="1">39 (23.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Unknow</td><td char="." align="char" colspan="1" rowspan="1">109 (44.7)</td><td char="." align="char" colspan="1" rowspan="1">33 (43.4)</td><td char="." align="char" colspan="1" rowspan="1">76 (45.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment lines</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">6.324</td><td char="." align="char" colspan="1" rowspan="1">0.042</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">164 (66.9)</td><td char="." align="char" colspan="1" rowspan="1">60 (77.9)</td><td char="." align="char" colspan="1" rowspan="1">104 (61.9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">48 (19.6)</td><td char="." align="char" colspan="1" rowspan="1">11 (14.3)</td><td char="." align="char" colspan="1" rowspan="1">37 (22.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">33 (13.5)</td><td char="." align="char" colspan="1" rowspan="1">6 (7.8)</td><td char="." align="char" colspan="1" rowspan="1">27 (16.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment plan</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">1.713</td><td char="." align="char" colspan="1" rowspan="1">0.425</td></tr><tr><td align="left" colspan="1" rowspan="1">ICI</td><td char="." align="char" colspan="1" rowspan="1">19 (7.8)</td><td char="." align="char" colspan="1" rowspan="1">7 (9.1)</td><td char="." align="char" colspan="1" rowspan="1">12 (7.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI plus chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">152 (62.0)</td><td char="." align="char" colspan="1" rowspan="1">51 (66.2)</td><td char="." align="char" colspan="1" rowspan="1">101 (60.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI plus chemotherapy plus targeted therapy</td><td char="." align="char" colspan="1" rowspan="1">74 (30.2)</td><td char="." align="char" colspan="1" rowspan="1">19 (24.7)</td><td char="." align="char" colspan="1" rowspan="1">55 (32.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Correlation between SIRI and the efficacy of tumor patients treated with ICI</title><p id="Par31">In the no-control group, the pre-treatment SIRI, disease remission SIRI, and disease progression SIRI were higher than those in the control group. However, a statistically significant difference in SIRI between the two groups was observed only when the disease progressed (<italic toggle="yes">P</italic>&#8201;=&#8201;0.018). Table&#160;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par32">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Analysis of SIRI between disease control group and no-control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Control group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;77</th><th align="left" colspan="1" rowspan="1">No-control group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;168</th><th align="left" colspan="1" rowspan="1">Z value</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td char="." align="char" colspan="1" rowspan="1">0.85 (0.34,1.18)</td><td char="." align="char" colspan="1" rowspan="1">1.19 (0.64,1.93)</td><td char="." align="char" colspan="1" rowspan="1">0.454</td><td char="." align="char" colspan="1" rowspan="1">0.650</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease remission</td><td char="." align="char" colspan="1" rowspan="1">0.35 (0.23,1.07)</td><td char="." align="char" colspan="1" rowspan="1">0.75 (0.50,1.40)</td><td char="." align="char" colspan="1" rowspan="1">0.563</td><td char="." align="char" colspan="1" rowspan="1">0.573</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease progression</td><td char="." align="char" colspan="1" rowspan="1">0.77 (0.34,1.08)</td><td char="." align="char" colspan="1" rowspan="1">1.08 (0.60,2.23)</td><td char="." align="char" colspan="1" rowspan="1">2.357</td><td char="." align="char" colspan="1" rowspan="1">0.018</td></tr></tbody></table></table-wrap>
</p><p id="Par33">Compared with before treatment, SIRI exhibited a downward trend in disease remission, which subsequently increased during disease progression. Except for the disease control group, where changes in disease remission and disease progression were not significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.091), the other variations were statistically significant (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), as shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par34">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Changes in SIRI during immunotherapy. **<italic toggle="yes">P</italic>&lt;0.001, ns: <italic toggle="yes">P</italic>&gt;0.05</p></caption><graphic id="d33e809" position="float" orientation="portrait" xlink:href="12672_2025_3521_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Correlation between SIRI and prognosis of tumor patients treated with ICI</title><p id="Par35">Based on whether the disease is under control, an ROC curve is constructed, and the optimal cut-off value for SIRI is determined using the Youden index. Subsequently, patients are categorized into high-SIRI group and low-SIRI group (Table <xref rid="Tab4" ref-type="table">4</xref>). The Kaplan-Meier survival curve analysis, employing the log-rank test, revealed the following results: Prior to immunotherapy, the median PFS for the high-SIRI group was 9.14 months [95% confidence interval (CI): 7.58&#8211;10.71], whereas for the low-SIRI group, it was 25.64 months (95% CI: 6.77&#8211;44.52). The difference between the two groups was statistically significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.022). At the time of disease remission, the median PFS for the high-SIRI group was 7.00 months (95% CI: 5.94&#8211;8.07), compared to 17.50 months (95% CI: 13.03&#8211;21.97) for the low-SIRI group, with a statistically significant difference between the groups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). During disease progression, the median PFS for the high-SIRI group was 6.11 months (95% CI: 5.10&#8211;7.12), whereas for the low-SIRI group, it was 7.93 months (95% CI: 6.17&#8211;9.69). The difference between the two groups was also statistically significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.013). These findings are illustrated in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.</p><p id="Par36">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Optimal limits values and grouping of SIRI</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Inflammatory index</th><th align="left" colspan="1" rowspan="1">Optimal limit value</th><th align="left" colspan="1" rowspan="1">Low-SIRI</th><th align="left" colspan="1" rowspan="1">High-SIRI</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Pre-treatment SIRI</td><td char="." align="char" colspan="1" rowspan="1">0.99</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.99</td><td char="." align="char" colspan="1" rowspan="1">&#8805;&#8201;0.99</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease remission SIRI</td><td char="." align="char" colspan="1" rowspan="1">0.76</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.76</td><td char="." align="char" colspan="1" rowspan="1">&#8805;&#8201;0.76</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease progression SIRI</td><td char="." align="char" colspan="1" rowspan="1">1.23</td><td char="." align="char" colspan="1" rowspan="1">&lt;1.23</td><td char="." align="char" colspan="1" rowspan="1">&#8805;&#8201;1.23</td></tr></tbody></table></table-wrap>
</p><p id="Par37">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Kaplan-Meier survival analyses of SIRI progression free survival (PFS) <bold>a</bold> pre-treatment; <bold>b</bold> disease remission; <bold>c</bold> disease progression</p></caption><graphic id="d33e899" position="float" orientation="portrait" xlink:href="12672_2025_3521_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Analysis of factors affecting the prognosis of patients with advanced cancer treated with ICI</title><p id="Par38">Disease progression was considered the dependent variable, while basic clinical characteristics, pre-treatment SIRI, disease remission SIRI, and disease progression SIRI were taken as independent variables. Univariate COX regression analysis indicate: Pre-treatment high SIRI [hazard ratio (HR) 2.22, 95%CI: 1.122&#8211;4.401, <italic toggle="yes">P</italic>&#8201;=&#8201;0.022], and disease remission high SIRI(HR 2.36, 95%CI:1.515&#8211;3.672, <italic toggle="yes">P</italic>&lt;0.001)and disease progression high SIRI (HR 1.478, 95% CI: 1.087&#8211;2.009, <italic toggle="yes">P</italic>&#8201;=&#8201;0.013) were poor prognostic factors for PFS in tumor patients with ICI. In contrast, gender, age, ECOG, differentiation degree, number of immunotherapy lines, and treatment plan did not significantly correlate with PFS (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05) (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). Further multivariate COX regression analysis revealed that pre-treatment SIRI (HR&#8201;=&#8201;2.804, 95% CI 1.150&#8201;~&#8201;6.838, <italic toggle="yes">P</italic>&#8201;=&#8201;0.023) and disease remission SIRI (HR&#8201;=&#8201;2.469, 95%CI 1.513&#8201;~&#8201;4.029, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) were independent risk factors affecting PFS. Detailed results are presented in Table&#160;<xref rid="Tab6" ref-type="table">6</xref>.</p><p id="Par39">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Univariate COX regression analysis on influencing factors for cancer patients treated with ICI</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">HR (95%CI)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender (male)</td><td char="." align="char" colspan="1" rowspan="1">1.064 (0.770&#8211;1.471)</td><td char="." align="char" colspan="1" rowspan="1">0.706</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (&#8805;&#8201;60)</td><td char="." align="char" colspan="1" rowspan="1">1.113 (0.821&#8211;1.508)</td><td char="." align="char" colspan="1" rowspan="1">0.491</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of metastatic organs (&#8805;&#8201;2)</td><td char="." align="char" colspan="1" rowspan="1">1.171 (0.862&#8211;1.591)</td><td char="." align="char" colspan="1" rowspan="1">0.313</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor differentiation (High/middle )</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Low</td><td char="." align="char" colspan="1" rowspan="1">1.005 (0.706&#8211;1.430)</td><td char="." align="char" colspan="1" rowspan="1">0.978</td></tr><tr><td align="left" colspan="1" rowspan="1">unknow</td><td char="." align="char" colspan="1" rowspan="1">1.006 (0.683&#8211;1.482)</td><td char="." align="char" colspan="1" rowspan="1">0.975</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment lines (1*)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">1.425 (0.979&#8211;2.074)</td><td char="." align="char" colspan="1" rowspan="1">0.065</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">1.371 (0.892&#8211;2.106)</td><td char="." align="char" colspan="1" rowspan="1">0.150</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment plan (ICI)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI plus chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">1.097 (0.602&#8211;2.002)</td><td char="." align="char" colspan="1" rowspan="1">0.762</td></tr><tr><td align="left" colspan="1" rowspan="1">ICI plus chemotherapy plus targeted therapy</td><td char="." align="char" colspan="1" rowspan="1">1.207 (0.645&#8211;2.257)</td><td char="." align="char" colspan="1" rowspan="1">0.556</td></tr><tr><td align="left" colspan="1" rowspan="1">Pre-treatment SIRI (High)</td><td char="." align="char" colspan="1" rowspan="1">2.222 (1.122&#8211;4.401)</td><td char="." align="char" colspan="1" rowspan="1">0.022</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease remission SIRI (High)</td><td char="." align="char" colspan="1" rowspan="1">2.358 (1.515&#8211;3.672)</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease progression SIRI (High)</td><td char="." align="char" colspan="1" rowspan="1">1.478 (1.087&#8211;2.009)</td><td char="." align="char" colspan="1" rowspan="1">0.013</td></tr></tbody></table><table-wrap-foot><p>*Contrast</p></table-wrap-foot></table-wrap>
</p><p id="Par40">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Multivariate COX regression analysis on influencing factors for cancer patients treated with ICI</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">SX</th><th align="left" colspan="1" rowspan="1">Wald &#967;<sup>2</sup></th><th align="left" colspan="1" rowspan="1">HR</th><th align="left" colspan="2" rowspan="1">95%CI<break/>Lower limit Upper limit</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Pre-treatment SIRI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Low SIRI</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">High SIRI</td><td align="left" colspan="1" rowspan="1">1.031</td><td char="." align="char" colspan="1" rowspan="1">0.455</td><td char="." align="char" colspan="1" rowspan="1">5.138</td><td char="." align="char" colspan="1" rowspan="1">2.804</td><td char="." align="char" colspan="1" rowspan="1">1.150</td><td char="." align="char" colspan="1" rowspan="1">6.838</td><td char="." align="char" colspan="1" rowspan="1">0.023</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease remission SIRI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Low SIRI</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">High SIRI</td><td align="left" colspan="1" rowspan="1">0.904</td><td char="." align="char" colspan="1" rowspan="1">0.250</td><td char="." align="char" colspan="1" rowspan="1">13.098</td><td char="." align="char" colspan="1" rowspan="1">2.469</td><td char="." align="char" colspan="1" rowspan="1">1.513</td><td char="." align="char" colspan="1" rowspan="1">4.029</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease progression SIRI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Low SIRI</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">High SIRI</td><td align="left" colspan="1" rowspan="1">0.117</td><td char="." align="char" colspan="1" rowspan="1">0.199</td><td char="." align="char" colspan="1" rowspan="1">0.344</td><td char="." align="char" colspan="1" rowspan="1">1.124</td><td char="." align="char" colspan="1" rowspan="1">0.761</td><td char="." align="char" colspan="1" rowspan="1">1.661</td><td char="." align="char" colspan="1" rowspan="1">0.557</td></tr></tbody></table><table-wrap-foot><p>*Contrast</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par41">ICI represents a novel form of immunotherapy drug that specifically targets PD-1 or PD-L1. It has been extensively utilized in treating various solid tumors, such as lung, gastric, esophageal, liver, colorectal cancers, and malignant melanoma [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].Both the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines have endorsed immunotherapy as a first-line treatment for the aforementioned advanced malignant tumors [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>].The advent of immunotherapy has transformed the treatment strategies for malignant tumors and has significantly extended the survival of patients with these cancers. Nonetheless, the majority of tumor patients experience primary or acquired drug resistance, with only a minority able to achieve durable responses to immunotherapy [<xref ref-type="bibr" rid="CR22">22</xref>]. Currently, there is an urgent need for sensitive biomarkers to predict the efficacy of immunotherapy.</p><p id="Par42">The tumor microenvironment is replete with a multitude of inflammatory cells and related mediators that not only foster the growth and metastasis of malignant tumors but also suppress the immune response and alter the sensitivity of tumor cells to antitumor drugs [<xref ref-type="bibr" rid="CR10">10</xref>]. During the process of tumor immunity, inflammatory cells such as neutrophils, lymphocytes, monocytes, and platelets play a pivotal role. Neutrophils, as a key component of the innate immune system, are involved in nearly all tumor processes, including tumor growth, metastasis, impaired immune surveillance, and treatment resistance [<xref ref-type="bibr" rid="CR23">23</xref>]. On the one hand, tumor associated neutrophils can mediate antitumor effects through direct cytotoxicity, and on the other hand, they can indirectly mediate antitumor effects through activating adaptive immune responses [<xref ref-type="bibr" rid="CR24">24</xref>].Monocytes and macrophages, as principal drivers of tumor-associated inflammation, create conditions for the occurrence and development of chronic inflammation-related tumors by secreting tumor necrosis factor and interleukins (such as interleukin 1&#946;, interleukin 6, interleukin 12). Simultaneously, they enhance the immunosuppressive tumor microenvironment by secreting cytokines (such as interleukin 10, transforming growth factor &#946;), thereby inhibiting the anti-tumor immune response [<xref ref-type="bibr" rid="CR25">25</xref>]. A study found that IFN &#947; could activate PI3K/AKT and JAK/STAT3 pathways in NSCLC, thereby enhancing PD-L1 expression. This mechanism suggested that IFN&#947; induced immunosuppression [<xref ref-type="bibr" rid="CR26">26</xref>]. Another study found that PD-1 blocked T cell proliferation and activation by disrupting the PI3K/AKT signal transduction pathway [<xref ref-type="bibr" rid="CR27">27</xref>].Studies have revealed that platelets play a crucial role in promoting and maintaining epithelial-mesenchymal transition, aiding circulating tumor cells in evading immune surveillance, and secreting pro-metastatic factors within the tumor microenvironment [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par43">SIRI is a novel inflammatory response marker that combines neutrophils, lymphocytes, or platelets, which is easy to obtain. Previous studies have shown that Siri can predict the survival outcomes of various solid tumors [<xref ref-type="bibr" rid="CR29">29</xref>]. Researchers both domestically and internationally have extensively studied the correlation between inflammatory indicators and tumors. Several studies have revealed that high levels of inflammatory indicators are closely associated with a low immune response and poor prognosis in gastric cancer, lung cancer, and other tumors [<xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref>]. A previous study on advanced tumors treated with ICI [<xref ref-type="bibr" rid="CR33">33</xref>] showed that the SIRI level in the disease progression group was higher than that in the disease control group. This was consistent with the conclusion of the current study and further confirmed the negative correlation between the Siri level and treatment efficacy.At present, the research on tumor diagnosis and prognosis prediction markers at home and abroad is still in progress, but these markers have not been widely used in all kinds of tumor patients. For example, Yang [<xref ref-type="bibr" rid="CR34">34</xref>] found that nucleolar and spindle associated protein 1 (PLIN3) was associated with M2 macrophage infiltration in a variety of tumors. High PLIN3 predicted shorter survival in patients with renal clear cell carcinoma, hepatocellular carcinoma and other tumors, but had a protective effect on thymoma and endometrial cancer.</p><p id="Par44">This study found that SIRI exhibited a downward trend following disease remission, but increased again as the disease progressed, and this fluctuation was statistically significant. This suggests that inflammatory indicators are valuable in predicting treatment outcomes for patients with malignant tumors undergoing ICI therapy. The underlying reason may be that the tumor inflammatory microenvironment plays a crucial role in tumor metastasis and the response to immunotherapy. As a biomarker of inflammatory response, the dynamic changes in SIRI may reflect the interaction between the tumor and the host immune system. Furthermore, the peripheral blood routine data collected in this study was from one month before disease remission and one month before disease progression, indicating that these inflammatory indicators are not only useful for predicting the efficacy of immunotherapy but may also serve as a tool for early monitoring of disease progression. This is particularly beneficial before imaging changes can indicate disease progression, aiding in the earlier detection of such changes.</p><p id="Par45">A study showed that the combination of SIRI and platelet lymphocyte ratio can effectively predict the prognosis of gastric cancer patients, and SIRI was confirmed to be an independent predictor of the overall survival of gastric cancer [<xref ref-type="bibr" rid="CR35">35</xref>]. Another study found that SIRI was significantly correlated with the prognosis of bladder cancer patients, and a high SIRI was an independent predictor of a higher recurrence-free survival rate [<xref ref-type="bibr" rid="CR36">36</xref>]. A meta-analysis [<xref ref-type="bibr" rid="CR37">37</xref>] involving 1,133 tumor patients demonstrated that in patients treated with ICI, a high SIRI was significantly associated with PFS and overall survival. The Kaplan-Meier survival curve analysis revealed that the median PFS for patients with higher SIRI levels was significantly shorter than for those with lower levels; Cox multivariate regression analysis further confirmed that SIRI before immunotherapy and at the time of disease remission were independent risk factors for PFS in tumor patients treated with ICI. This suggests that in clinical practice, inflammatory indicators should be considered alongside traditional prognostic factors to more comprehensively evaluate the treatment response and prognosis of patients. In the future, a deeper study of these inflammatory indicators may lead to more personalized treatment strategies for tumor patients, thereby enhancing treatment outcomes and prognosis.</p><p id="Par46">The method employed in this study is straightforward and accessible, with inflammatory indicators that are readily obtainable in a clinical setting. Dynamic analysis of Siri can monitor the treatment response in real time, so as to achieve rapid treatment adjustment.The findings indicate that SIRI, an inflammatory index, could serve as a potential biomarker for predicting treatment efficacy and evaluating the prognosis of malignant tumor patients undergoing ICI therapy. However, this study also has some limitations: Firstly, this study is not a single cancer, and there is heterogeneity among different cancers without further analysis of the correlation between inflammatory markers and the efficacy of different cancers or pathological subtypes; Secondly, the inflammatory indicators included in this study are relatively limited, and other inflammation related indicators such as interferon-&#947;, tumor associated macrophages, and interleukins were not included. In the future, we will explore and validate the practical value of inflammatory markers in predicting the efficacy and prognosis of immunotherapy for malignant tumors by expanding the sample size and range of inflammatory markers. And further analyze the correlation between inflammatory indicators and different cancer or pathological subtypes. At the same time, we will also attempt to combine more clinical information, such as patients&#8217; genetic mutations, immune status, etc., to comprehensively analyze the role of inflammatory indicators in immunotherapy for malignant tumors, and provide more accurate treatment for patients.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par47">In conclusion, SIRI can be a dynamic biomarker for evaluating the efficacy and prognosis of advanced cancer patients receiving ICI treatment. However, whether SIRI is applicable to guide the selection of treatment is not known. SIRI also must be validated prospectively before it can be accepted in the majority of the institutes.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Xiuzhen Wei, Yinghai Liu, Huijuan Wang and Qingqing Yang contributed equally to this work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Z-ZJ designed the study. W-XZ, L-YH, W-HJ and Y-QQ performed the work and drafted the manuscript, They contributed equally to this work and should be considered co-first anthors. Z-BH, L-QY, Z-Y and Z-LL contributed to interpreting the data and refined the drafted manuscript. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Wuwei Science and Technology Bureau (project number WW24B01SF087).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data supporting the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes><title>Ethics approval and consent to participate</title><p id="Par48">This study was approved by the Ethics Committee of Wuwei Liangzhou Hospital and was performed in accordance with the ethical standards described in the Declaration of Helsinki. Informed consent for this study was obtained using the opt-out system with the approval of the ethics committee</p></notes><notes><title>Informed consent</title><p id="Par49">Informed consent was obtained from the participants to participate in the current study.</p></notes><notes><title>Consent to publication</title><p id="Par50">All authors read and approved to publish the final manuscript.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#8211;63.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janjigian</surname><given-names>YY</given-names></name><name name-style="western"><surname>Shitara</surname><given-names>K</given-names></name><name name-style="western"><surname>Moehler</surname><given-names>M</given-names></name><etal/></person-group><article-title>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><issue>10294</issue><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">34102137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00797-2</pub-id><pub-id pub-id-type="pmcid">PMC8436782</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27&#8211;40.<pub-id pub-id-type="pmid">34102137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00797-2</pub-id><pub-id pub-id-type="pmcid">PMC8436782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rha</surname><given-names>SY</given-names></name><name name-style="western"><surname>Oh</surname><given-names>DY</given-names></name><name name-style="western"><surname>Ya&#241;ez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><issue>11</issue><fpage>1181</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">37875143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00515-6</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Rha SY, Oh DY, Ya&#241;ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181&#8211;95.<pub-id pub-id-type="pmid">37875143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00515-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garassino</surname><given-names>MC</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S</given-names></name><name name-style="western"><surname>Speranza</surname><given-names>G</given-names></name><etal/></person-group><article-title>Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>11</issue><fpage>1992</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">36809080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01989</pub-id><pub-id pub-id-type="pmcid">PMC10082311</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992&#8211;8.<pub-id pub-id-type="pmid">36809080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01989</pub-id><pub-id pub-id-type="pmcid">PMC10082311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Combination strategies with PD-1/PD-L1 blockade: current advances and future directions</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>28</fpage><pub-id pub-id-type="pmid">35062949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01489-2</pub-id><pub-id pub-id-type="pmcid">PMC8780712</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.<pub-id pub-id-type="pmid">35062949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01489-2</pub-id><pub-id pub-id-type="pmcid">PMC8780712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>943389</fpage><pub-id pub-id-type="pmid">36003381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.943389</pub-id><pub-id pub-id-type="pmcid">PMC9393426</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wang H, Liu J, Yang J, et al. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Front Immunol. 2022;13:943389.<pub-id pub-id-type="pmid">36003381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.943389</pub-id><pub-id pub-id-type="pmcid">PMC9393426</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Cercek</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunotherapy in colorectal cancer: rationale, challenges and potential</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2019</year><volume>16</volume><issue>6</issue><fpage>361</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">30886395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0126-x</pub-id><pub-id pub-id-type="pmcid">PMC7295073</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361&#8211;75.<pub-id pub-id-type="pmid">30886395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0126-x</pub-id><pub-id pub-id-type="pmcid">PMC7295073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGrail</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Pili&#233;</surname><given-names>PG</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>NU</given-names></name><etal/></person-group><article-title>High tumor mutation burden fails to predict immune checkpoint Blockade response across all cancer types</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>5</issue><fpage>661</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">33736924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.02.006</pub-id><pub-id pub-id-type="pmcid">PMC8053682</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">McGrail DJ, Pili&#233; PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint Blockade response across all cancer types. Ann Oncol. 2021;32(5):661&#8211;72.<pub-id pub-id-type="pmid">33736924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.02.006</pub-id><pub-id pub-id-type="pmcid">PMC8053682</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elinav</surname><given-names>E</given-names></name><name name-style="western"><surname>Nowarski</surname><given-names>R</given-names></name><name name-style="western"><surname>Thaiss</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><issue>11</issue><fpage>759</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24154716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3611</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759&#8211;71.<pub-id pub-id-type="pmid">24154716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>J</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><issue>5</issue><fpage>261</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">33469195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00459-9</pub-id><pub-id pub-id-type="pmcid">PMC8978805</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261&#8211;79.<pub-id pub-id-type="pmid">33469195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00459-9</pub-id><pub-id pub-id-type="pmcid">PMC8978805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gungabeesoon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gort-Freitas</surname><given-names>NA</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>M</given-names></name><etal/></person-group><article-title>A neutrophil response linked to tumor control in immunotherapy</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>7</issue><fpage>1448</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">37001504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.02.032</pub-id><pub-id pub-id-type="pmcid">PMC10132778</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Gungabeesoon J, Gort-Freitas NA, Kiss M, et al. A neutrophil response linked to tumor control in immunotherapy. Cell. 2023;186(7):1448&#8211;64.<pub-id pub-id-type="pmid">37001504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.02.032</pub-id><pub-id pub-id-type="pmcid">PMC10132778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivennikov</surname><given-names>SI</given-names></name><name name-style="western"><surname>Greten</surname><given-names>FR</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Immunity, inflammation, and cancer</article-title><source>Cell</source><year>2010</year><volume>140</volume><issue>6</issue><fpage>883</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">20303878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.01.025</pub-id><pub-id pub-id-type="pmcid">PMC2866629</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883&#8211;99.<pub-id pub-id-type="pmid">20303878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.01.025</pub-id><pub-id pub-id-type="pmcid">PMC2866629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Liver tumour immune microenvironment subtypes and neutrophil heterogeneity</article-title><source>Nature</source><year>2022</year><volume>612</volume><issue>7938</issue><fpage>141</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">36352227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05400-x</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Xue R, Zhang Q, Cao Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141&#8211;7.<pub-id pub-id-type="pmid">36352227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05400-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>N</given-names></name><name name-style="western"><surname>Yin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>6578</fpage><pub-id pub-id-type="pmid">38503890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-57343-0</pub-id><pub-id pub-id-type="pmcid">PMC10951263</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Pang J, Ding N, Yin N, et al. Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy. Sci Rep. 2024;14(1):6578.<pub-id pub-id-type="pmid">38503890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-57343-0</pub-id><pub-id pub-id-type="pmcid">PMC10951263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and Atezolizumab</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><issue>11</issue><fpage>3199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">33796915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-021-02926-3</pub-id><pub-id pub-id-type="pmcid">PMC10991671</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Qi WX, Xiang Y, Zhao S, et al. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and Atezolizumab. Cancer Immunol Immunother. 2021;70(11):3199&#8211;206.<pub-id pub-id-type="pmid">33796915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-021-02926-3</pub-id><pub-id pub-id-type="pmcid">PMC10991671</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Peng</surname><given-names>G</given-names></name><etal/></person-group><article-title>The prognostic value of peripheral blood inflammatory markers in hepatocellular carcinoma treated with lenvatinib combined with PD-1 inhibitors</article-title><source>J Hepatocell Carcinoma</source><year>2025</year><volume>12</volume><fpage>135</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">39877858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JHC.S486910</pub-id><pub-id pub-id-type="pmcid">PMC11774115</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Xin Y, Liu N, Peng G, et al. The prognostic value of peripheral blood inflammatory markers in hepatocellular carcinoma treated with lenvatinib combined with PD-1 inhibitors. J Hepatocell Carcinoma. 2025;12:135&#8211;47.<pub-id pub-id-type="pmid">39877858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JHC.S486910</pub-id><pub-id pub-id-type="pmcid">PMC11774115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>S</given-names></name><name name-style="western"><surname>Raychaudhuri</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immune checkpoint therapy-current perspectives and future directions</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>8</issue><fpage>1652</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">37059068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.006</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652&#8211;69.<pub-id pub-id-type="pmid">37059068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name><name name-style="western"><surname>Terashima</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YW</given-names></name><etal/></person-group><article-title>Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Gastroenterol Hepatol</source><year>2024</year><volume>9</volume><issue>8</issue><fpage>705</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">38906161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(24)00156-0</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705&#8211;17.<pub-id pub-id-type="pmid">38906161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(24)00156-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>HH</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kour</surname><given-names>O</given-names></name><etal/></person-group><article-title>Association of PD-L1 expression and other variables with benefit from immune checkpoint Inhibition in advanced gastroesophageal cancer: systematic review and Meta-analysis of 17 phase 3 randomized clinical trials</article-title><source>JAMA Oncol</source><year>2022</year><volume>8</volume><issue>10</issue><fpage>1456</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">36006624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.3707</pub-id><pub-id pub-id-type="pmcid">PMC9412834</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint Inhibition in advanced gastroesophageal cancer: systematic review and Meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022;8(10):1456&#8211;65.<pub-id pub-id-type="pmid">36006624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.3707</pub-id><pub-id pub-id-type="pmcid">PMC9412834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Shah</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><issue>10302</issue><fpage>759</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">34454674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01234-4</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759&#8211;71.<pub-id pub-id-type="pmid">34454674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01234-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YL</given-names></name><name name-style="western"><surname>Kudaba</surname><given-names>I</given-names></name><etal/></person-group><article-title>Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial</article-title><source>Lancet</source><year>2019</year><volume>393</volume><issue>10183</issue><fpage>1819</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">30955977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32409-7</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Mok T, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819&#8211;30.<pub-id pub-id-type="pmid">30955977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32409-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>J</given-names></name><name name-style="western"><surname>Ha</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Network-based machine learning approach to predict immunotherapy response in cancer patients</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>3703</fpage><pub-id pub-id-type="pmid">35764641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31535-6</pub-id><pub-id pub-id-type="pmcid">PMC9240063</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kong J, Ha D, Lee J, et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1):3703.<pub-id pub-id-type="pmid">35764641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31535-6</pub-id><pub-id pub-id-type="pmcid">PMC9240063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Quail DF, Amulic B, Aziz M et al. Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med, 2022,219(6):e20220011.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20220011</pub-id><pub-id pub-id-type="pmcid">PMC9086501</pub-id><pub-id pub-id-type="pmid">35522219</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tumor-Educated neutrophils activate mesenchymal stem cells to promote gastric cancer growth and metastasis</article-title><source>Front Cell Dev Biol</source><year>2020</year><volume>8</volume><fpage>788</fpage><pub-id pub-id-type="pmid">32903528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.00788</pub-id><pub-id pub-id-type="pmcid">PMC7438587</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhang J, Ji C, Li W, et al. Tumor-Educated neutrophils activate mesenchymal stem cells to promote gastric cancer growth and metastasis. Front Cell Dev Biol. 2020;8:788.<pub-id pub-id-type="pmid">32903528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.00788</pub-id><pub-id pub-id-type="pmcid">PMC7438587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maiorino</surname><given-names>L</given-names></name><name name-style="western"><surname>Da&#223;ler-Plenker</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>Innate immunity and cancer pathophysiology</article-title><source>Annu Rev Pathol</source><year>2022</year><volume>17</volume><fpage>425</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">34788549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathmechdis-032221-115501</pub-id><pub-id pub-id-type="pmcid">PMC9012188</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Maiorino L, Da&#223;ler-Plenker J, Sun L, et al. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17:425&#8211;57.<pub-id pub-id-type="pmid">34788549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathmechdis-032221-115501</pub-id><pub-id pub-id-type="pmcid">PMC9012188</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Non-immune cell components in tumor microenvironment influencing lung cancer immunotherapy</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>166</volume><fpage>115336</fpage><pub-id pub-id-type="pmid">37591126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115336</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhang J, Liu S, Chen X, et al. Non-immune cell components in tumor microenvironment influencing lung cancer immunotherapy. Biomed Pharmacother. 2023;166:115336.<pub-id pub-id-type="pmid">37591126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gianchecchi</surname><given-names>E</given-names></name><name name-style="western"><surname>Delfino</surname><given-names>DV</given-names></name><name name-style="western"><surname>Fierabracci</surname><given-names>A</given-names></name></person-group><article-title>Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity</article-title><source>Autoimmun Rev</source><year>2013</year><volume>12</volume><issue>11</issue><fpage>1091</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">23792703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2013.05.003</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12(11):1091&#8211;100.<pub-id pub-id-type="pmid">23792703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2013.05.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>C</given-names></name><name name-style="western"><surname>Koupenova</surname><given-names>M</given-names></name><name name-style="western"><surname>Machlus</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer</article-title><source>J Thromb Haemost</source><year>2022</year><volume>20</volume><issue>7</issue><fpage>1523</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">35441793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.15733</pub-id><pub-id pub-id-type="pmcid">PMC9321119</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Desai C, Koupenova M, Machlus KR, et al. Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer. J Thromb Haemost. 2022;20(7):1523&#8211;34.<pub-id pub-id-type="pmid">35441793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.15733</pub-id><pub-id pub-id-type="pmcid">PMC9321119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1143154</fpage><pub-id pub-id-type="pmid">37064093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1143154</pub-id><pub-id pub-id-type="pmcid">PMC10098186</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhang J, Zhang L, Duan S, et al. Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis. Front Oncol. 2023;13:1143154.<pub-id pub-id-type="pmid">37064093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1143154</pub-id><pub-id pub-id-type="pmcid">PMC10098186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The clinical value of the combined detection of systemic Immune-Inflammation index (SII), systemic inflammation response index (SIRI), and prognostic nutritional index (PNI) in early diagnosis of gastric cancer</article-title><source>J Inflamm Res</source><year>2025</year><volume>18</volume><fpage>813</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">39845022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S496703</pub-id><pub-id pub-id-type="pmcid">PMC11752871</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zheng J, Zheng L, Wang X, et al. The clinical value of the combined detection of systemic Immune-Inflammation index (SII), systemic inflammation response index (SIRI), and prognostic nutritional index (PNI) in early diagnosis of gastric cancer. J Inflamm Res. 2025;18:813&#8211;26.<pub-id pub-id-type="pmid">39845022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S496703</pub-id><pub-id pub-id-type="pmcid">PMC11752871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Midik MM, Gunenc D, Acar PF et al. Prognostic value of Blood-Based inflammatory markers in cancer patients receiving immune checkpoint inhibitors. Cancers (Basel), 2024,17(1):37.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17010037</pub-id><pub-id pub-id-type="pmcid">PMC11719015</pub-id><pub-id pub-id-type="pmid">39796668</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><etal/></person-group><article-title>AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers</article-title><source>Int Immunopharmacol</source><year>2025</year><volume>149</volume><fpage>114215</fpage><pub-id pub-id-type="pmid">39904040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2025.114215</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhou Y, Liu X, Wu B, et al. AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers. Int Immunopharmacol. 2025;149:114215.<pub-id pub-id-type="pmid">39904040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2025.114215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study</article-title><source>World J Surg Oncol</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>198</fpage><pub-id pub-id-type="pmid">37420219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-023-03077-8</pub-id><pub-id pub-id-type="pmcid">PMC10326931</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zheng F, Meng Q, Zhang L, et al. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study. World J Surg Oncol. 2023;21(1):198.<pub-id pub-id-type="pmid">37420219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-023-03077-8</pub-id><pub-id pub-id-type="pmcid">PMC10326931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The role of PLIN3 in prognosis and Tumor-Associated macrophage infiltration: A Pan-Cancer analysis</article-title><source>J Inflamm Res</source><year>2025</year><volume>18</volume><fpage>3757</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">40098998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S509245</pub-id><pub-id pub-id-type="pmcid">PMC11913039</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yang S, Liu H, Zheng Y, et al. The role of PLIN3 in prognosis and Tumor-Associated macrophage infiltration: A Pan-Cancer analysis. J Inflamm Res. 2025;18:3757&#8211;77.<pub-id pub-id-type="pmid">40098998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S509245</pub-id><pub-id pub-id-type="pmcid">PMC11913039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical significance of systemic inflammation response index and platelet-lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><issue>4</issue><fpage>e26176</fpage><pub-id pub-id-type="pmid">38420481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e26176</pub-id><pub-id pub-id-type="pmcid">PMC10900425</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Fang T, Yin X, Wang Y, et al. Clinical significance of systemic inflammation response index and platelet-lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. Heliyon. 2024;10(4):e26176.<pub-id pub-id-type="pmid">38420481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e26176</pub-id><pub-id pub-id-type="pmcid">PMC10900425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Russo P, Foschi N, Palermo G et al. SIRI as a biomarker for bladder neoplasm: utilizing decision curve analysis to evaluate clinical net benefit. Urol Oncol, 2025:393.e1&#8211;393.e8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2025.01.007</pub-id><pub-id pub-id-type="pmid">39934058</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis</article-title><source>Ann Med</source><year>2024</year><volume>56</volume><issue>1</issue><fpage>2413415</fpage><pub-id pub-id-type="pmid">39383059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2024.2413415</pub-id><pub-id pub-id-type="pmcid">PMC11465384</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Gu X, Han X, Shen Y, et al. Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis. Ann Med. 2024;56(1):2413415.<pub-id pub-id-type="pmid">39383059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2024.2413415</pub-id><pub-id pub-id-type="pmcid">PMC11465384</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>